Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Multicenter, Randomized, Double-Blinded, Study to Describe the Safety, Efficacy, and Pharmacokinetics of Daptomycin 10 mg/kg/Day and Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus Aureus Bacteremia

Trial Profile

A Phase 2 Multicenter, Randomized, Double-Blinded, Study to Describe the Safety, Efficacy, and Pharmacokinetics of Daptomycin 10 mg/kg/Day and Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus Aureus Bacteremia

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daptomycin (Primary) ; Vancomycin
  • Indications Bacteraemia; Bacterial endocarditis; Methicillin-resistant Staphylococcus aureus infections
  • Focus Adverse reactions
  • Acronyms HDSAB
  • Sponsors Cubist Pharmaceuticals
  • Most Recent Events

    • 12 Sep 2012 Results presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 01 Nov 2011 Primary endpoint identified as (Enzyme-levels and Serum-creatinine-levels) as reported by ClinicalTrials.gov.
    • 30 Sep 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top